Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch® Ventricular Restor
Designation Allows for Expedited Review of Transcatheter Therapy Designed to Improve Left Ventricular Structure and Function in Heart Failure Patients with Reduced Ejection FractionSANTA CLARA, Calif.--(BUSINESS WIRE)--#accucinch--Ancora Heart, Inc., a company developing a novel device-based therapy to address heart...
Source: pharmiweb.com